Global (United States, European Union and China) Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2019-2025

Choose License

Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market.  Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market?s growth.
In 2019, the market size of Benign Prostatic Hyperplasia (BPH) Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Benign Prostatic Hyperplasia (BPH) Drugs. 

This report studies the global market size of Benign Prostatic Hyperplasia (BPH) Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia). 
This study presents the Benign Prostatic Hyperplasia (BPH) Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025. 
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
    Astellas Pharma
    Eli Lilly
    GlaxoSmithKline
    Sanofi
    ADC Therapeutics
    Bayer HealthCare
    Bristol-Myers Squibb
    Valeant Pharmaceuticals
    Endo Pharmaceuticals
    Foresee Pharmaceuticals

Market Segment by Product Type
    Alpha-Blocker
    Phosphodiesterase Type-5 Inhibitors
    5-Alpha-Reductase Inhibitors

Market Segment by Application
    Men
    Women

Key Regions split in this report: breakdown data for each region.
    United States
    China
    European Union
    Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
    To analyze and research the Benign Prostatic Hyperplasia (BPH) Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
    To present the key Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
    To split the breakdown data by regions, type, companies and applications 
    To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
    To identify significant trends, drivers, influence factors in global and regions
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Benign Prostatic Hyperplasia (BPH) Drugs are as follows:
    History Year: 2014-2018
    Base Year: 2018
    Estimated Year: 2019
    Forecast Year 2019 to 2025
Table of Contents

1 Report Overview
    1.1 Study Scope
    1.2 Major Manufacturers Covered in This Report
    1.3 Market Segment by Type
        1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type (2019-2025)
        1.3.2 Alpha-Blocker
        1.3.3 Phosphodiesterase Type-5 Inhibitors
        1.3.4 5-Alpha-Reductase Inhibitors
    1.4 Market Segment by Application
        1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application (2019-2025)
        1.4.2 Men
        1.4.3 Women
    1.5 Study Objectives
    1.6 Years Considered

2 Global Growth Trends
    2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size
        2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2014-2025
        2.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2014-2025
    2.2 Benign Prostatic Hyperplasia (BPH) Drugs Growth Rate by Regions
        2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions 2014-2019
        2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions 2014-2019
    2.3 Industry Trends
        2.3.1 Market Top Trends
        2.3.2 Market Drivers

3 Market Share by Manufacturers
    3.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers
        3.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers 2014-2019
        3.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers 2014-2019
    3.2 Revenue by Manufacturers
        3.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2014-2019)
        3.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2014-2019)
        3.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Ratio (CR5 and HHI)
    3.3 Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturers
    3.4 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Plants/Factories Distribution and Area Served
    3.5 Date of Key Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
    3.6 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
    3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
    4.1 Sales and Revenue for Each Type
        4.1.1 Alpha-Blocker Sales and Revenue (2014-2019)
        4.1.2 Phosphodiesterase Type-5 Inhibitors Sales and Revenue (2014-2019)
        4.1.3 5-Alpha-Reductase Inhibitors Sales and Revenue (2014-2019)
    4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type
    4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type
    4.4 Benign Prostatic Hyperplasia (BPH) Drugs Price by Type

5 Market Size by Application
    5.1 Overview
    5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application

6 United States
   6.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
   6.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Type
   6.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Application

7 European Union
   7.1 European Union Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
   7.2 European Union Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Type
   7.3 European Union Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Application

8 China
   8.1 China Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
   8.2 China Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Type
   8.3 China Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Application

9 Rest of World
    9.1 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
    9.2 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Type
    9.3 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Application
    9.4 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Countries
        9.4.1 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries
        9.4.2 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries
        9.4.3 Japan
        9.4.4 Korea
        9.4.5 India
        9.4.6 Southeast Asia

10 Company Profiles
    10.1 Astellas Pharma
        10.1.1 Astellas Pharma Company Details
        10.1.2 Company Description and Business Overview
        10.1.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
        10.1.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
        10.1.5 Astellas Pharma Recent Development
    10.2 Eli Lilly
        10.2.1 Eli Lilly Company Details
        10.2.2 Company Description and Business Overview
        10.2.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
        10.2.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
        10.2.5 Eli Lilly Recent Development
    10.3 GlaxoSmithKline
        10.3.1 GlaxoSmithKline Company Details
        10.3.2 Company Description and Business Overview
        10.3.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
        10.3.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
        10.3.5 GlaxoSmithKline Recent Development
    10.4 Sanofi
        10.4.1 Sanofi Company Details
        10.4.2 Company Description and Business Overview
        10.4.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
        10.4.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
        10.4.5 Sanofi Recent Development
    10.5 ADC Therapeutics
        10.5.1 ADC Therapeutics Company Details
        10.5.2 Company Description and Business Overview
        10.5.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
        10.5.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
        10.5.5 ADC Therapeutics Recent Development
    10.6 Bayer HealthCare
        10.6.1 Bayer HealthCare Company Details
        10.6.2 Company Description and Business Overview
        10.6.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
        10.6.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
        10.6.5 Bayer HealthCare Recent Development
    10.7 Bristol-Myers Squibb
        10.7.1 Bristol-Myers Squibb Company Details
        10.7.2 Company Description and Business Overview
        10.7.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
        10.7.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
        10.7.5 Bristol-Myers Squibb Recent Development
    10.8 Valeant Pharmaceuticals
        10.8.1 Valeant Pharmaceuticals Company Details
        10.8.2 Company Description and Business Overview
        10.8.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
        10.8.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
        10.8.5 Valeant Pharmaceuticals Recent Development
    10.9 Endo Pharmaceuticals
        10.9.1 Endo Pharmaceuticals Company Details
        10.9.2 Company Description and Business Overview
        10.9.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
        10.9.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
        10.9.5 Endo Pharmaceuticals Recent Development
    10.10 Foresee Pharmaceuticals
        10.10.1 Foresee Pharmaceuticals Company Details
        10.10.2 Company Description and Business Overview
        10.10.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
        10.10.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
        10.10.5 Foresee Pharmaceuticals Recent Development

11 Value Chain and Sales Channels Analysis
    11.1 Value Chain Analysis
    11.2 Sales Channels Analysis
        11.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels
        11.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
    11.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers

12 Market Forecast
    12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue Forecast 2019-2025
    12.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type
    12.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application
    12.4 Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions
        12.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions 2019-2025
        12.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Regions 2019-2025
    12.5 United States Market Forecast
    12.6 European Union Market Forecast
    12.7 China Market Forecast
    12.8 Rest of World
        12.8.1 Japan
        12.8.2 Korea
        12.8.3 India

13 Research Findings and Conclusion

14 Appendix
    14.1 Research Methodology
        14.1.1 Methodology/Research Approach
            14.1.1.1 Research Programs/Design
            14.1.1.2 Market Size Estimation
            14.1.1.3 Market Breakdown and Data Triangulation
        14.1.2 Data Source
            14.1.2.1 Secondary Sources
            14.1.2.2 Primary Sources
    14.2 Author Details
    14.3 Disclaimer

List of Tables and Figures Figure Benign Prostatic Hyperplasia (BPH) Drugs Product Picture Table Benign Prostatic Hyperplasia (BPH) Drugs Key Market Segments Table Major Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Covered in This Report Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type 2019-2025 (K MT) & (Million US$) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Shar by Type 2014-2025 Figure Alpha-Blocker Figures Table Major Manufacturers of Alpha-Blocker Figure Phosphodiesterase Type-5 Inhibitors Figures Table Major Manufacturers of Phosphodiesterase Type-5 Inhibitors Figure 5-Alpha-Reductase Inhibitors Figures Table Major Manufacturers of 5-Alpha-Reductase Inhibitors Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application 2019-2025 (K MT) Figure Men Use Case Figure Women Use Case Figure Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size 2014-2025 (Million US$) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2014-2019 (K MT) Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Regions 2014-2019 (K MT) & (Million US$) Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions 2014-2019 (K MT) Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions 2014-2019 Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions 2014-2019 Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions in 2019 Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions 2014-2019 (Million US$) Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions 2014-2019 Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions 2014-2019 Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2019 Table Market Top Trends Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2014-2019) (K MT) Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers (2014-2019) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers in 2019 Table Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2014-2019) (Million USD) Table Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2014-2019) Figure Benign Prostatic Hyperplasia (BPH) Drugs Value Share by Manufacturers in 2019 Table Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) Table Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Price (2014-2019) (USD/MT) Table Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Plants/Factories Distribution Table Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Area Served Table Date of Key Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market Table Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type Table Mergers & Acquisitions, Expansion Plans Table Global Alpha-Blocker Sales and Revenue (2014-2019) (K MT) & (Million US$) Table Global Phosphodiesterase Type-5 Inhibitors Sales and Revenue (2014-2019) (K MT) & (Million US$) Table Global 5-Alpha-Reductase Inhibitors Sales and Revenue (2014-2019) (K MT) & (Million US$) Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2014-2019) (K MT) Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2014-2019) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2014-2019) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2018 Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2014-2019) (Million US$) Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2014-2019) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2014-2019) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type in 2018 Table Benign Prostatic Hyperplasia (BPH) Drugs Price by Type 2014-2019 (USD/MT) Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2014-2019) (K MT) Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2014-2019) Figure Global Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application (2014-2019) Figure Global Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application (2014-2019) Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT) Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$) Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2014-2019) (K MT) Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2014-2019) Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019 Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2014-2019) (K MT) Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2014-2019) Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2019 Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2014-2019) (K MT) Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2014-2019) Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2019 Figure European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT) Figure European Union Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$) Table European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2014-2019) (K MT) Table European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2014-2019) Figure European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019 Table European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2014-2019) (K MT) Table European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2014-2019) Figure 2018 European Union Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type Table European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2014-2019) (K MT) Table European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2014-2019) Figure 2018 European Union Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT) Figure China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$) Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2014-2019) (K MT) Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2014-2019) Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019 Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2014-2019) (K MT) Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2014-2019) Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2019 Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2014-2019) (K MT) Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2014-2019) Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2019 Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT) Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$) Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2014-2019) (K MT) Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2014-2019) Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019 Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2014-2019) (K MT) Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2014-2019) Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2019 Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2014-2019) (K MT) Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2014-2019) Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2019 Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2014-2019) (K MT) Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2014-2019) Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2019 Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2014-2019) (Million US$) Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2014-2019) Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2019 Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT) Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (K MT) Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT) Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (K MT) Figure India Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT) Figure India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (K MT) Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT) Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (K MT) Table Astellas Pharma Company Details Table Astellas Pharma Description and Business Overview Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019) Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market Table Astellas Pharma Recent Development Table Eli Lilly Company Details Table Eli Lilly Description and Business Overview Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019) Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market Table Eli Lilly Recent Development Table GlaxoSmithKline Company Details Table GlaxoSmithKline Description and Business Overview Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019) Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market Table GlaxoSmithKline Recent Development Table Sanofi Company Details Table Sanofi Description and Business Overview Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019) Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market Table Sanofi Recent Development Table ADC Therapeutics Company Details Table ADC Therapeutics Description and Business Overview Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019) Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market Table ADC Therapeutics Recent Development Table Bayer HealthCare Company Details Table Bayer HealthCare Description and Business Overview Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019) Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market Table Bayer HealthCare Recent Development Table Bristol-Myers Squibb Company Details Table Bristol-Myers Squibb Description and Business Overview Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019) Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market Table Bristol-Myers Squibb Recent Development Table Valeant Pharmaceuticals Company Details Table Valeant Pharmaceuticals Description and Business Overview Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019) Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market Table Valeant Pharmaceuticals Recent Development Table Endo Pharmaceuticals Company Details Table Endo Pharmaceuticals Description and Business Overview Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019) Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market Table Endo Pharmaceuticals Recent Development Table Foresee Pharmaceuticals Company Details Table Foresee Pharmaceuticals Description and Business Overview Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019) Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market Table Foresee Pharmaceuticals Recent Development Figure Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Table Benign Prostatic Hyperplasia (BPH) Drugs Distributors List Table Benign Prostatic Hyperplasia (BPH) Drugs Customers List Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT) & (Million US$) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$) Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type 2019-2025 (K MT) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type 2019-2025 (K MT) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type 2019-2025 Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application 2019-2025 (K MT) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application 2019-2025 (K MT) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application 2019-2025 Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions 2019-2025 (K MT) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions 2019-2025 (K MT) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Regions 2019-2025 Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Regions 2019-2025 (K MT) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Regions 2019-2025 (K MT) Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Regions 2019-2025 Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT) Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$) Figure European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT) Figure European Union Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$) Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT) Figure China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$) Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT) Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$) Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT) Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$) Figure India Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT) Figure India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$) Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT) Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$) Table Research Programs/Design for This Report Figure Bottom-up and Top-down Approaches for This Report Figure Data Triangulation Table Key Data Information from Secondary Sources Table Key Data Information from Primary Sources

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Other Reports by QY Research

Global (United States, European Union and China) Micro Gas Generator Market Research Report 2019-2025

A micro gas generator is a device that acts to retract the seatbelt (seatbelt pretensioner) in the event of a collision.The retraction of the seatbelt fixes the body to the ideal position in relation to the inflated airbag. This increases the effecti...

Global (United States, European Union and China) Medical Stools Market Research Report 2019-2025

A medical stool is a convenient stool for healthcare professionals while attending to patients. In 2019, the market size of Medical Stools is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China...

Global (United States, European Union and China) Manual Pipettes Market Research Report 2019-2025

A pipette (sometimes spelled pipet) is a laboratory tool commonly used in chemistry, biology and medicine to transport a measured volume of liquid, often as a media dispenser. In 2019, the market size of Manual Pipettes is xx million US$ and it will...

Global (United States, European Union and China) Isopropyl Alcohol (IPA) Market Research Report 2019-2025

Isopropyl alcohol is a compound with the chemical formula C3H8O. It is a colorless, flammable chemical compound with a strong odor. The key driver for the growth of the global isopropyl alcohol market is the surging demand for the product as a solve...

Global (United States, European Union and China) Insect Growth Regulators Market Research Report 2019-2025

Insect growth regulator is a kind of specific insecticide, which does not directly kill insects when used, but blocks or interferes with normal development of insects during the period of individual development, so as to reduce the living capacity of...

New Pharmaceuticals and Healthcare Reports